Statement of Work Request for Information

STATEMENT OF WORK

1. PURPOSE

The overall purpose is to acquire the Y-90 microspheres (SIR Spheres) intended for intra-arterial radiation therapy (radioembolization) to liver tumors. These doses are used in procedures for the Interventional Radiology Department at Michael E. DeBakey VA Medical Center. This transaction will be to set up a Base plus 4 option year agreement with the vendor Sirtex Medical.

2. SCOPE

Contractor shall provide the doses and support services in the Interventional Radiology (IR) section of the Michael E DeBakey VA Medical Center, 2002 Holcombe Blvd, Houston, Texas 77030. All services shall be done in a first-class manner and must meet manufacturers and VA specifications.

3. BACKGROUND

•

•
•
•
•

Limited Treatment Options: Patients with liver cancer who are candidates for Y-90 may have limited alternatives for targeted therapy. This can reduce their options to other treatments, which may not be as effective or suitable.
Disease Progression: Delay or inability to provide Y-90 treatment may allow cancer to progress, potentially decreasing the chances of successful treatment outcomes and overall survival rates. Increased Burden on Other Treatments: Hospitals may need to rely more heavily on other forms of treatment like systemic chemotherapy, surgery, or other forms of radiation therapy. This could lead to higher demand and potential shortages in other therapeutic areas. Patient Well-Being: The effectiveness and targeted nature of Y-90 treatments help minimize damage to surrounding healthy tissue, which is beneficial for patient well-being. Without access to Y-90, patients may experience more side effects and a decline in their quality of life. Health Care Costs: Alternative treatments that are less geographically targeted may lead to increased healthcare costs due to extended hospital stays, additional medications, and more intensive care requirements.
Clinical Trials and Research: The inability to provide Y-90 might impact ongoing clinical trials and research studies focused on evaluating the therapy's effectiveness and exploring new indications for use. This can stall advancements in treatment protocols.

T
AF

•

R

D

Y-90 (Yttrium-90) is a targeted liver cancer therapy used in the treatment of hepatocellular carcinoma (HCC) and other liver tumors. It is a form of radioembolization where Y-90, a radioactive isotope, is delivered directly to the liver tumors through tiny beads. Currently there are two Y-90 products available, Theraspheres, which we currently use at MEDVAMC, and SIR-Spheres. Because we currently utilize